Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics

Author(s):
Reichardt, P.; Joensuu, H.; Casali, P.G.; Kang, Y.K.; Blay, J.Y.; Rutkowski, P.; Gelderblom, H.; Hohenberger, P.; Leahy, M.G.; Mehren, M. von; Badalamenti, G.; Blackstein, M.E.; Cesne, A. le; Schoffski, P.; Maki, R.G.; Xu, J.M.; Nishida, T.; Kappeler, C.; Kuss, I.; Demetri, G.D.
Published
2014
Publication type
Article / Letter to editor
Date issued
2014-02-28
Language
English
Is part of
Oncology Research and Treatment (2014), Vol. 37, p. 57-57
hdl
1887/107671